Odronextamab, a bispecific antibody targeting CD20 and CD3, led to response rates as high as 90 percent in patients with refractory B-cell non-Hodgkin lymphoma (B-NHL), including patients who underwent chimeric antigen receptor (CAR) T cell therapy, according to early trials results.
ASH 2020: Chemotherapy-Free Combination Treatment for Chronic Lymphocytic Leukemia Reveals High One-Year Disease-Free Survival Rate
A time-limited, frontline combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) shows to mobilize and clear CLL leading to deep responses for patients who achieved undetectable minimal residual disease (MRD) status, according to results from the CAPTIVATE study.
ASH 2020: ZUMA-12 Trial Exhibits Promising Results in Frontline CAR T Treatment for Aggressive Lymphoma
Axicabtagene ciloleucel (axi-cel), a chimeric antigen receptor (CAR) T cell therapy, appeared an effective frontline (initial) treatment for high-risk large B-cell lymphomas.
The white paper provides a summary of the workshop proceedings, presents the key findings of each speaker, and highlights the unmet needs identified during the post-workshop discussion with suggested immediate and long-term solutions.
LRF Showcases Impressive Number of Researchers at 2020 American Society of Hematology Annual Meeting
LRF Scientific Advisory Board Members joined by current and former grantees at the 62nd ASH Annual Meeting & Exposition
Dr. Manali Kamdar’s unique and empathetic approach to patient care and lymphoma research leaves a lasting impact on the lymphoma community.
Established through the generosity of the Peykoff Family and Niagara Cares, the $10 million Initiative is poised to transform the follicular lymphoma treatment landscape for tens of thousands of patients by harnessing LRF’s unique resources, convening the world’s experts in follicular lymphoma research and patient care, and driving direct investment in clinical research.
Projects awarded from this year’s class of CDA and Postdoctoral Fellows include early clinical trials of novel therapies, investigations into the biology of Hodgkin lymphoma and aggressive non-Hodgkin lymphomas, and new mechanisms for chimeric antigen receptor (CAR) T cell therapy.
The new class of LRF Scholars is pursuing research projects covering a diverse range of lymphoma subtypes with a goal to improve patient outcomes.
Dr. Kara Kelly is helping to build the bridge between AYA, and pediatric and adult oncology fields to bring attention to this underserved population and improve patient care.